K. Corona

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.

Sourav K. Mishra, J. Sancho, R. Bouabdallah, 2020, The Lancet. Haematology.

Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.

J. Sancho, U. Jaeger, Xiwen Ma, 2021, Clinical lymphoma, myeloma & leukemia.

Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study

A. Azmi, Yiwei Li, J. Shah, 2021, Clinical Cancer Research.

Artroscopia de la rodilla con anestesia local

K. Corona, Rivera Hernández, C. M. Rohenes, 1996 .

The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study

J. Sancho, U. Jaeger, G. Follows, 2022, Cancers.

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

J. Sancho, U. Jaeger, Xiwen Ma, 2021, Journal of Hematology & Oncology.

A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Sourav K. Mishra, J. Sancho, R. Bouabdallah, 2019, Clinical Lymphoma, Myeloma & Leukemia.